Data from Pharmawand - Curated by EPG Health - Date added 23 October 2013

NeuroAiD, from Moleac, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months in patients after Stroke onset, without an increase in bleeding rate and non-vascular deaths according to research published in the journal Stroke. The CHIMES study is an international double-blind placebo-controlled clinical trial in 1099 patients having suffered an ischemic stroke of intermediate severity within 72 hours, treated by NeuroAiD or placebo and monitored for 3 months.

NeuroAiD may have an effect on preventing the occurrence of early vascular events after stroke onset: the vascular outcome occurred in 16 patients (2.9%) of the NeuroAiD group, as opposed to 31 patients (5.6%) in the placebo group. This represents half the rate of early cardiovascular events and deaths, which corresponds to about 27 fewer patients suffering a recurrent vascular event or death per 1000 patients treated over 3 months. Patients on NeuroAiD having fewer adverse events than those in the placebo group. See: "Effects of MLC601 on Early Vascular Events in Patients After Stroke: The CHIMES Study." Chen CLH et al. Stroke 2013; 44 October 17, 2013. doi: 10.1161/STROKEAHA.113.003226

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more

Related Content